The E2F-1 transcription factor is a critical downstream target of the tumor suppressor, RB. When activated, E2F-1 induces cell proliferation. In addition, deregulation of E2F-1 constitutes an oncogenic stress that can induce apoptosis. The protein kinase ATM is a pivotal mediator of the response to another type of stress, genotoxic stress. In response to ionizing radiation, ATM activates the tumor suppressor p53, a key player in the control of cell growth and viability. We show here that E2F-1 elevates ATM promoter activity and induces an increase in ATM mRNA and protein levels. This is accompanied by an E2F-induced increase in p53 phosphorylation. Expression of the E7 protein of HPV16, which dissociates RB/E2F complexes, also induces the elevation of ATM levels and p53 phosphorylation, implicating endogenous E2F in these phenomena. These data demonstrate that ATM is transcriptionally regulated by E2F-1 and suggest that ATM serves as a novel, ARF-independent functional link between the RB/E2F pathway and p53.
Introduction
The E2F family of transcription factors plays a crucial role in the control of cell proliferation (Dyson, 1998; Nevins, 1998) . E2F regulates the expression of many genes required for entry into and progression through the S phase of the cell cycle (Dyson, 1998; Nevins, 1998) , and overexpression of E2F induces S phase entry of quiescent cells (Johnson et al., 1993) . E2F activity is negatively regulated by the product of the retinoblastoma tumor suppressor, RB, and the growth suppression activity of RB is dependent on its ability to interact with E2F (Dyson, 1998; Nevins, 1998) . The RB pathway is often mutated in human cancer, resulting in deregulated E2F activity. Deregulated E2F-1 constitutes an oncogenic stress that can induce apoptosis via both p53-dependent and p53-independent pathways (Qin et al., 1994; Kowalik et al., 1995; Philips et al., 1997) . E2F1-induced activation of p53 is believed to be mediated to a large extent by p14 ARF , which is transcriptionally activated by E2F and functions in the stabilization and activation of p53 by negating the effects of mdm2 on p53 (reviewed in Sherr and Weber, 2000) . Recent studies suggest that deregulated E2F-1 elevates the expression of genes involved in the response to genotoxic stress including BRCA1 and RAD51 (Wang et al., 2000a; Ishida et al., 2001; Polager et al., 2002; Ren et al., 2002; Weinmann et al., 2002) . The E2F-1 protein is stabilized and its levels are elevated in response to DNA damage (Blattner et al., 1999; O'Connor and Lu, 1999; Lin et al., 2001) , further supporting a role for this transcription factor in the DNA damage response. A pivotal mediator of genotoxic stress is the protein kinase ATM (ataxia-telangiectasia, mutated). In response to ionizing radiation, ATM induces phosphorylation of various cellular proteins, including key players in the control of the cell cycle checkpoints such as p53, mdm2, Cdc25C and BRCA1 (reviewed in Shiloh, 2001) . These phosphorylations inhibit the mdm2-p53 interaction, thus contributing to p53 stabilization and activation.
We show here that E2F-1 can transactivate the ATM promoter. Furthermore, deregulated E2F-1 induces an increase in ATM levels and a concomitant increase in p53 phosphorylation. Both p53 phosphorylation and E2F1-induced apoptosis are inhibited by the ATM/ ATR inhibitor caffeine, suggesting that ATM is an important mediator of E2F-1 activity.
Results
To determine whether E2F and ATM are functionally linked, we tested the responsiveness of the ATM promoter to E2F-1. The ATM promoter is a bidirectional promoter regulating the expression of both ATM and NPAT (Byrd et al., 1996; Imai et al., 1997) . Interestingly, NPAT promotes replication-dependent histone gene transcription, which is a key S phase event (Ma et al., 2000; Zhao et al., 2000) . The distance between the human ATM and NPAT transcription start sites is 519 base pairs and this small bidirectional promoter contains five putative E2F-binding sites (Figure 1f) , three of which, at positions À462, À453 and À399, are also conserved in the murine promoter (Byrd et al., 1996) . We cloned the human promoter in both orientations into luciferase reporter plasmids. Cotransfection of these reporters together with an E2F-1 expression vector into NIH3T3 cells resulted in Figure 1 The ATM promoter is responsive to E2F-1. (a) The ATM/NPAT bidirectional promoter is activated by E2F-1 in both orientations. NIH3T3 cells were transfected with both the ATM-firefly luciferase (ATM) and NPAT-renilla luciferase (NAPT) reporters and pCMV-b-Gal, either alone (None) or with an expression vector of wtE2F-1 (E2F-1). Cell extracts were prepared 48 h after transfection and used for a dual luciferase assay and b-Gal assay. The bar graph depicts fold activation in the luciferase assay, after normalization for b-Gal activity. (b) Upregulation of ATM promoter by E2F-1 requires transcriptionally active E2F-1. NIH3T3 cells were transfected with the ATM-luciferase reporter plasmid and pCMV-b-Gal, either alone (None) or with indicated expression vectors -wtE2F-1 (E2F-1), a transcriptionally inactive E2F-1 (E2F-1DTA) and DP-1 (DP-1). Cell extracts were prepared 48 h after transfection and used for a luciferase andb-Gal assay. The bar graph depicts fold activation in the luciferase assay, after normalization for b-Gal activity. (c) E2F-1, but not DNA damage, upregulates ATM promoter activity. NIH3T3 cells were transfected with the ATM-luciferase reporter and pCMV-b-Gal, either alone (À) or with an expression vector of E2F-1 (+). At 24 h after transfection, the cells were either harvested (À) or exposed to g-irradiation (10 Gy), and then incubated for the indicated times before harvesting. Cell extracts were prepared and used for luciferase assay as in (a). (d) Deletion of a short segment containing an E2F site results in a reduction of activation of the ATM promoter by E2F-1. NIH3T3 cells were transfected with expression vector of E2F-1, pCMV-b-GAL reporter and either ATM-luc or the indicated promoter deletion constructs of the ATM-luc. Cell extracts were prepared 48 h after transfection and used for luciferase and b-Gal assay. Fold of activation in the luciferase assay with (black bars) or without (blank bars) E2F-1, after normalization for b-Gal activity, is depicted in the bar graph. (e) E2F-1 and E2F-3 activate the ATM promoter. NIH3T3 cells were transfected with the ATM-luc reporter and pCMV-b-Gal, either alone (None) or with an expression vector of HA-E2F-1 (E2F-1), HA-E2F-2 (E2F-2) or HA-E2F-3 (E2F-3). Cell extracts were prepared 48 h after transfection and used for a luciferase assay and b-Gal assay. The bar graph depicts fold activation in the luciferase assay, after normalization for b-Gal activity. All experiments in (a-e) were performed in duplicate. (f) Schematic representation of the human bidirectional promoter of ATM/NPAT (Imai et al., 1996) and its deletion constructs. E2F sites are presented as blank boxes and 8-mer nucleotide sequences. The position of the E2F binding sites relative to the ATM transcription start site is indicated E2F-induced activation of this promoter in both orientations ( Figure 1a ). The ATM promoter was further activated by coexpression of E2F-1 and its heterodimeric partner, DP-1 (Figure 1b ). The ATM promoter was not activated by an E2F-1 mutant lacking the transactivation domain, E2F-1DTA, indicating that this activation requires a transcriptionally active E2F-1 (Figure 1b) . Furthermore, the ATM promoter was not activated by g-irradiation and its activation by E2F-1 was not enhanced by g-irradiation (Figure 1c ). The lack of change in ATM promoter activity in response to DNA damage is consistent with previous results demonstrating that the DNA damage-induced activation of ATM is not accompanied by changes in ATM levels (Banin et al., 1998; Canman et al., 1998; Khanna et al., 1998) . These data suggest that DNA damage and E2F-1 regulate ATM via distinct mechanisms. To further elucidate the regulation of the ATM promoter by E2F-1, we performed a deletion analysis of the ATM promoter. Deletion of the distal 85 base pairs of the ATM promoter, which include two putative E2F-binding sites, did not affect the basal activity of this promoter and resulted in a mild reduction of ATM promoter activation by E2F-1. Further deletion of a 44 bp segment that contains a conserved E2F-binding site, at position À399, also did not affect the basal activity; however, it caused a significant reduction in ATM promoter activation by E2F-1, implicating this site as a binding site for E2F-1 (Figure 1d , f). EMSA indicated that an oligonucleotide containing this E2F-binding site indeed binds E2F-1 (data not shown). We next tested whether other E2F family members could activate the ATM promoter. When E2F-1, -2 and -3 were expressed at similar levels, E2F-2 expression resulted in a mild increase in ATM promoter activity, while expression of E2F-3 or E2F-1 led to a significant increase in ATM luciferase activity, suggesting that E2F-1 and -3 can efficiently activate the ATM promoter.
Next, NIH3T3 cells were infected with retroviruses containing either wild-type E2F-1, E2F-1DTA, or an
Figure 2 E2F-1 upregulates ATM mRNA, protein and activity. (a) Levels of ATM mRNA are elevated by wtE2F-1. NIH3T3 cells were infected with a pBabe-puro retroviral vector (Vector) or with a retrovirus harboring either wild-type E2F-1 (E2F-1) or a transcriptionally inactive E2F-1 (E2F-1DTA). At 20 h after infection, puromycin was added to the cultures for 24 h. Total RNA was extracted from the cells using the Tri Reagent method (MRC, TR-118). RT-PCR was performed on the total RNA using specific primers for the ATM and GAPDH genes. (b) Transactivation of ATM by E2F-1 does not require de novo protein synthesis. NIH3T3 cells were infected with pBabe-ER-E2F-1. At 48 h postinfection, cells were incubated with OHT, cycloheximide (CHX) or both for 4 h. Total RNA was extracted from the cells as in (a). RT-PCR was performed on the total RNA using specific primers for the ATM and GAPDH genes. (c) E2F-1, but not DNA damage, upregulates ATM mRNA level. NIH3T3 cells were infected with a pBabe-puro retroviral vector (Vector) or with a retrovirus harboring wild-type E2F-1 (E2F-1). At 20 h after infection puromycin was added to the cultures for 24 h, and in the last 10 h cisplatin (4 mg/ml) was added to the medium. Total RNA was prepared from the cells as in (a). RT-PCR was performed on the total RNA using specific primers for the ATM and GAPDH genes. (d) The NPAT mRNA level is upregulated by E2F-1. NIH3T3 cells were infected with a pBabe-puro retroviral vector (Vector) or a retrovirus harboring wild-type E2F-1 (E2F-1). Total RNA was prepared from the cells as in (a) and used for RT-PCR with NPAT-and GAPDH-specific primers. (e) Levels of ATM protein and p53 phosphorylation at Ser 15 are elevated by wtE2F-1. Proteins were extracted from the cells described in (a). Equal amounts of protein extracts were used for Western blot analysis with antibodies specific for ATM antibody (MAT3), p53 (CM-5) or p53-phosphorylated Ser15 (#9284, Cell Signaling) empty retroviral vector. wtE2F-1 and E2F-1DTA were expressed at similar levels (data not shown); however, expression of wtE2F-1, but not E2F-1DTA, resulted in an increase in endogenous ATM mRNA levels (Figure 2a) . Similar results were obtained using mouse embryo fibroblasts (MEFs) (data not shown). To determine whether ATM is a direct target of E2F, we infected NIH3T3 cells with a retrovirus carrying E2F-1 fused to the estrogen receptor ligand-binding domain (ER-E2F-1). The ER-E2F-1 is expressed as an inactive fusion protein in the cytoplasm. Upon addition of the ligand 4-hydroxytamoxifen (OHT), the ER-E2F-1 translocates to the nucleus and transactivates E2F-regulated genes (Vigo et al., 1999) . As can be seen in Figure 2b , addition of OHT led to an increase in ATM mRNA levels both in the absence and presence of the protein synthesis inhibitor cycloheximide (CHX). These data indicate that de novo protein synthesis is not required for E2F1-induced upregulation of the ATM mRNA, thus suggesting that ATM is a direct target of E2F-1.
The DNA-damaging agent cisplatin did not increase ATM mRNA levels nor did it significantly enhance the E2F1-induced increase of ATM mRNA levels (Figure 2c ). This further supports the notion that DNA damage and E2F-1 regulate ATM via distinct mechanisms. NPAT mRNA levels were also upregulated by E2F-1, further corroborating the promoter activity data (Figure 2d ).
ATM protein levels were similarly increased upon expression of wtE2F-1, but not E2F-1DTA (Figure 2e) . Expression of E2F-1 resulted in a mild but reproducible increase in endogenous p53 protein levels and, most notably, led to a marked phosphorylation of mouse p53 on serine 18 (the equivalent of serine 15 in human p53; will be referred to hereafter as serine 15) (Figure 2e ). Phosphorylation of p53 at serine 15 is ATM-dependent (Banin et al., 1998; Canman et al., 1998; Khanna et al., 1998) . Thus, this increase in p53 serine 15 phosphorylation indicates that the E2F-induced ATM is active.
To study the regulation of ATM expression by endogenous E2F, we infected NIH3T3 cells with a retrovirus containing the E7 gene of HPV16, which dissociates RB/E2F complexes. Expression of E7 abrogates the p16/cyclin D-Cdk4/RB pathway, leading to deregulation of E2F activity. Such deregulation is very common in human tumors. In parallel, cells were infected with a mutated E7, E7D21-35, which does not bind RB family members. Expression of these wt and mutated E7 did not affect the protein levels of endogenous E2F-1 (Figure 3b ). However, although the wt and mutated E7 were expressed at similar levels, expression of wt E7, but not E7D21-35, led to an increase in ATM mRNA and protein levels (Figure 3a , b). Concomitantly with this accumulation of ATM, wt E7, but not E7D21-35, induced p53 phosphorylation on serine 15 (Figure 3b ). These data strongly suggest that deregulated endogenous E2F elevates expression of endogenous ATM and induces phosphorylation of endogenous p53.
As can be seen in Figure 4 , activation of ER-E2F-1 in U2OS cells, which lack functional p14 ARF , resulted in an increase in p53 serine 15 phosphorylation accompanied by a marked increase in apoptosis. Addition of caffeine, an inhibitor of ATM/ATR activity, led to a decrease in both p53 serine 15 phosphorylation and the E2F1-induced apoptosis. These data indicate that ATM and/ or ATR mediate E2F1-induced p53 phosphorylation and contribute to E2F1-induced apoptosis. siRNA for p53 also significantly inhibited E2F1-induced apoptosis (Figure 4) , further supporting an ARF independent functional link between the RB/E2F pathway and p53.
Discussion
Pre-existing ATM protein is rapidly activated in response to ionizing radiation via mechanisms that have not been elucidated (Banin et al., 1998; Canman et al., 1998; Khanna et al., 1998) . No changes in ATM protein level are detected following irradiation exposure (Brown et al., 1997; Watters et al., 1997) , suggesting that posttranslational mechanisms govern ATM activation. Furthermore, the ATM protein level remains constant Figure 3 WT E7, but not mutant E7 defective in RB-binding, elevates ATM levels and p53 phosphorylation. NIH3T3 cells were infected with a pBabe-puro retroviral vector (Vector) or with a retrovirus harboring either wild-type E7 (E7) or an RB-binding deficient mutant of E7 (E7D21-35). Protein and total RNA were extracted from the cells as in Figure 2 . (a) RT-PCR was performed on the total RNA using ATM-, E7-and GAPDH-specific primers. (b) Equal amounts of protein extracts were used for Western blot analysis with antibodies directed against ATM (MAT3), E2F-1 (sc-251, Santa Cruz), p53 (CM-5) and p53-phosphorylatedser15 (#9284, Cell Signaling) throughout the cell cycle (Brown et al., 1997) . Our data indicate that ectopic expression of E2F-1 activates the ATM promoter and elevates both ATM mRNA and protein levels. Importantly, we show that deregulation of endogenous E2F also elevates ATM mRNA and protein levels. The oncogenic stress exerted by deregulated E2F-1 activity may use such transcriptional regulation to feed into signal transduction pathways that function in the response to genotoxic stress. Consequently, E2F-1 deregulation may sensitize cells to DNA damage. This could explain the increased sensitivity of cancer cells to killing by DNA-damaging chemotherapeutic agents.
It remains to be determined whether the E2F-induced elevation of ATM expression is sufficient to increase ATM activity, or whether this upregulated ATM needs to be further activated. ATM resides in a large multisubunit protein complex (Wang et al., 2000b) , and many of the proteins in this complex are encoded by E2F-regulated genes. These include BRCA1, the DNA repair proteins MSH2 and MSH6, DNA replication factor C (RFC) and PCNA (Wang et al., 2000a; Polager et al., 2002) . This raises the possibility that several components of this complex are coregulated by E2F. Like ATM, MSH2 and BRCA1 are not cell cycle regulated, suggesting that these proteins are part of an emerging group of E2F-regulated genes that have functions distinct from cell cycle control. Indeed, recent studies using DNA microarray analysis and promoter binding assays identified many putative E2F-regulated genes that are not cell cycle related (Ishida et al., 2001; Muller et al., 2001; Polager et al., 2002; Ren et al., 2002) .
Expression of Chk1, a kinase that mediates activity of the ATM-related kinase ATR in response to DNA damage, was shown to be downregulated by p53 in a p21-and RB-dependent manner (Gottifredi et al., 2001) , and its promoter binds E2F (Ren et al., 2002) . Similarly, E2F was shown to bind the promoter of another DNA damage responsive kinase, DNA-dependent protein kinase (DNA-PK) catalytic subunit (Ren et al., 2002) . Moreover, ectopic expression of E2F-1 leads to an increase in mRNA levels of both Chk1 and DNA-PK (EB and DG, unpublished data). These data suggest that a number of DNA damage responsive kinases are regulated by E2F, raising the interesting possibility that E2F modulates the levels of critical regulators of the DNA damage response pathways in a coordinated fashion. It remains to be determined whether other DNA damage-responsive kinases are also regulated by E2F.
Interestingly, the E2F1-induced upregulation of ATM described here is not the only functional link between these two proteins and ATM was shown to phosphorylate E2F-1 in response to DNA damage, leading to its stabilization (Lin et al., 2001) .
The RB/E2F pathway and p53 are two key regulators of cell growth and viability. One known functional link between E2F and p53 is p14 ARF , which is transcriptionally activated by E2F and functions in stabilization and activation of p53 by negating the effects of mdm2 on p53 (reviewed in Sherr and Weber, 2000) . However, overexpression of E2F-1 increases p53 protein levels in cells lacking ARF (Zindy et al., 1998) , and deregulated E2F can induce p53-dependent, ARF-independent apoptosis (Russell et al., 2002; Tolbert et al., 2002; Tsai et al., 2002 and Figure 4) . Furthermore, recent studies demonstrate that E2F-1 can induce phosphorylation of p53 in the absence of ARF, suggesting an additional functional link between E2F-1 and p53 (Rogoff et al., 2002 and Figure 4; Russell et al., 2002) . The data presented here suggest that the upregulation of ATM expression by E2F-1 may be part of this novel, ARFindependent functional link between the RB/E2F pathway and p53.
Methods

Cell culture
NIH 3T3 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% bovine calf serum (BCS). 293 and U2OS cells were grown in DMEM supplemented with 10% FCS. Cells were maintained at 371C in a humidified 8% CO 2 -containing atmosphere. To induce activation of ER-E2F-1, cells were treated with OHT (300 nm) for Figure 4 Caffeine and p53 siRNA inhibit E2F-1-mediated p53 Ser 15 phosphorylation and apoptosis. U2OS cells stably expressing the ER-E2F-1 fusion protein were incubated with OHT, caffeine or both for 16 h. Cells were harvested for FACS and Western blot analysis. The percentage of cells with Sub-G1 DNA content, as determined by FACS analysis, is depicted in the bar graph. Equal amounts of protein extracts were used for Western blot analysis with antibodies directed against ATM (MAT3), E2F-1 (sc-251, Santa-Cruz), p53 (DO-1/1-801) and p53-phosphorylated ser15 (#9284, Cell Signaling). The same cells were infected with pRetroSuper-siRNAp53 and analysed as above 4-16 h. Cycloheximide (Sigma) was used for 4 h (10 mg/ml). Caffeine (Sigma) was used at a range of 5-7.5 mm for 16 h.
Western blotting
Cells were lysed in lysis buffer (50 mm Tris pH 7.5, 150 mm NaCl, 1 mm EDTA, 1% NP-40, phenylmethylsulfonyl fluoride (43 mg/ml), aprotinin (17 mg/ml), leupeptin (5 mg/ml), NaF (25 mm), NaVO 3 (1 mm)). Equal amounts of protein from each lysate, as determined by Bradford assay, were resolved by electrophoresis in an SDS 10% polyacrylamide gel for p53 and E2F-1 or a 7.5% gel for ATM, and then transferred to a filter (Protran BA 85, S&S). The filter was incubated overnight with the following antibodies: anti-ATM antibody (MAT3), a-p53 (CM-5), a-p53-ser15 phosphorylation (#9284, Cell Signaling) or a-E2F-1 (sc-251, Santa Cruz). Binding of the primary antibody was detected using an enhanced chemiluminescence kit (ECL, Amersham).
RT-PCR and isolation of human ATM promoter
Total RNA was extracted from the cells using the Tri Reagent method (MRC, TR-118). Reverse transcription-PCR (RT-PCR) was performed as previously described (Polager et al., 2002) . A 530 bp fragment of the ATM promoter from À521 to +9 was generated by PCR using human genomic T98G DNA as template and 60 pm each from the 5 0 and 3 0 primers: 5 0 -CCCCTCGAGGCGACAGCTCCTGCGCCGCATCTCC-3 0 and 5 0 -CCCAAGCTTCCTCTCGCCTCCTCCCGTGGCC-3 0 .
Plasmids
The luciferase reporter plasmid ATM (À512 to +9) Luc was constructed by subcloning the 530 bp XhoI/HindIII fragment of the ATM promoter into pGL3-basic-Luc. The NPAT-luc reporter was constructed from the ATM-luc by cloning a Klenow-treated 530 bp XhoI/HindIII fragment into a pRL-null renilla luciferase vector and verifying the correct NPAT promoter orientation. The deletions of the E2F sites in the ATM promoter were performed using 5 0 -CCCCTCGAGGC-CAGCCAATCGCTTCCGC-3 0 for the À436 ATM-luc and 5 0 -CCCCTCGAGGCCCCGCCTCCGTTCGCC-3 0 for the À392 ATM-luc, together with the 5 0 oligo used for isolating the ATM promoter. All constructs were verified by sequencing.
The following plasmids have been previously described: pRcCMV-HA-E2F-1, pRcCMV-HA-E2F-2 and pRcCMV-HA-E2F-3 (Xu et al., 1995) ; pCMV-b-Gal (Lindeman et al., 1997) , pcDNAI-E2F-1, pCMV-DP-1, pBabe-E2F-1 (Krek et al., 1993) , pRcCMV-HA-E2F-1(1-363) (Hofmann et al., 1996) ; pBABE-HA-ER-E2F-1 (Vigo et al., 1999) . pBABE-E2F-1dlTA was generated by inserting the E2F-1dlTA XbaIHindIII fragment from pRcCMV-E2F-1(1-363) (Hofmann et al., 1996) into the pBABE-puro vector. pRetroSuperp53siRNA was generated by inserting the EcoRI/HindIII fragment from pSuper-p53siRNA (gift of Reuven Agami) into the pRetroSuper vector.
Transfection and infection assays 293 cells were transfected by the calcium phosphate method. NIH3T3 cells were transfected by LipofectAMINE reagent (Life Technologies, Inc.). Infection, cell lysis, b-Gal and luciferase assays were performed essentially as described (Lindeman et al., 1997; Berkovich and Ginsberg, 2001) . At 20 h after infection, 2 mg/ml puromycin was added to the cultures for 24-48 h.
FACS analysis
Cells were trypsinized and fixed with 70% ethanol (41C, overnight). After fixation, cells were centrifuged for 5 min at 1200 r.p.m., and incubated for 30 min at 41C in 1 ml of PBS, centrifuged and resuspended in PBS containing 5 mg/ml propidium iodide for 20 min at room temperature. The cells were analysed using a Becton Dickinson flow cytometer.
